There was also significant upregulation of FLT1, AKT, ERK1, ERK2, LCN2, COL1A1, TUBB, and VCL in the AD and MCS populations; increased FLK1, FN1, and COL4A5 expression in the MCS population, and increased LAMB2, CDH1, RAF1, MEK1, SRC1, and MTOR expression in the AD population. This evidence concerns the gene MAP2K1 and Alzheimer disease.